MX2022010925A - Compuestos para su uso en afecciones autoinmunitarias. - Google Patents

Compuestos para su uso en afecciones autoinmunitarias.

Info

Publication number
MX2022010925A
MX2022010925A MX2022010925A MX2022010925A MX2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A MX 2022010925 A MX2022010925 A MX 2022010925A
Authority
MX
Mexico
Prior art keywords
compounds
autoimmune conditions
treatment
autoimmune
conditions
Prior art date
Application number
MX2022010925A
Other languages
English (en)
Inventor
Marín Pablo Avilés
González Alejandro Losada
Sousa-Faro José María Fernández
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of MX2022010925A publication Critical patent/MX2022010925A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K11/00Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K11/02Depsipeptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof cyclic, e.g. valinomycins ; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/15Depsipeptides; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Genetics & Genomics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biochemistry (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere al uso de compuestos en el tratamiento de afecciones autoinmunitarias y en particular, para el tratamiento de la artritis reumatoide.
MX2022010925A 2020-03-02 2021-03-02 Compuestos para su uso en afecciones autoinmunitarias. MX2022010925A (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP20382152 2020-03-02
EP20382192 2020-03-13
EP20382266 2020-04-02
EP20382339 2020-04-27
EP20382815 2020-09-16
EP20382814 2020-09-16
EP21382059 2021-01-25
PCT/EP2021/055142 WO2021175829A1 (en) 2020-03-02 2021-03-02 Compounds for use in autoimmune conditions

Publications (1)

Publication Number Publication Date
MX2022010925A true MX2022010925A (es) 2022-09-29

Family

ID=74732952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022010925A MX2022010925A (es) 2020-03-02 2021-03-02 Compuestos para su uso en afecciones autoinmunitarias.

Country Status (16)

Country Link
US (1) US20230158104A1 (es)
EP (1) EP4114432A1 (es)
JP (1) JP2023517537A (es)
KR (1) KR20220148896A (es)
CN (1) CN115867286A (es)
AU (1) AU2021229592A1 (es)
BR (1) BR112022017129A2 (es)
CA (1) CA3169557A1 (es)
CL (1) CL2022002397A1 (es)
CO (1) CO2022014023A2 (es)
IL (1) IL296070A (es)
MX (1) MX2022010925A (es)
PE (1) PE20231101A1 (es)
TW (1) TW202146039A (es)
UY (1) UY39111A (es)
WO (1) WO2021175829A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8922026D0 (en) * 1989-09-29 1989-11-15 Pharma Mar Sa Novel anti-viral and cytotoxic agent
US6156724A (en) * 1996-06-07 2000-12-05 Rinehart; Kenneth L. Uses of didemnins as immunomodulating agents
GB9803448D0 (en) 1998-02-18 1998-04-15 Pharma Mar Sa Pharmaceutical formulation
DK1276491T3 (da) 2000-04-07 2007-02-05 Univ Pennsylvania Tamandarin- og didemnin-analoger og fremgangsmåder til fremstilling og anvendelse af dem
UA76718C2 (uk) 2000-06-30 2006-09-15 Фарма Мар, С.А. Протипухлинні похідні аплідину
EP1613338A4 (en) 2003-03-21 2009-06-24 Madeleine M Joullie TAMANDARIN ANALOGUES, FRAGMENTS THEREOF AND METHODS OF MAKING AND USING THE SAME
WO2011020913A2 (en) 2009-08-21 2011-02-24 Pharma Mar, S.A. Cyclodepsipeptide antiviral compounds

Also Published As

Publication number Publication date
BR112022017129A2 (pt) 2022-10-11
TW202146039A (zh) 2021-12-16
KR20220148896A (ko) 2022-11-07
CO2022014023A2 (es) 2022-11-18
JP2023517537A (ja) 2023-04-26
US20230158104A1 (en) 2023-05-25
CN115867286A (zh) 2023-03-28
CA3169557A1 (en) 2021-09-10
CL2022002397A1 (es) 2023-06-30
AU2021229592A1 (en) 2022-09-29
UY39111A (es) 2021-09-30
IL296070A (en) 2022-11-01
WO2021175829A1 (en) 2021-09-10
EP4114432A1 (en) 2023-01-11
PE20231101A1 (es) 2023-07-18

Similar Documents

Publication Publication Date Title
PH12020551463A1 (en) Pd-1 agonist antibodies and uses thereof.
CA3156451A1 (en) ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
PH12020500033A1 (en) Macrocyclic compounds and uses thereof
MY192848A (en) Compositions and methods for the treatment of hemoglobinopathies
MX2022011546A (es) Composiciones y metodos para el agotamiento de celulas cd137+.
MX2022001061A (es) Agentes de interleuquina-2 y usos de los mismos.
ZA202207804B (en) Compounds and uses thereof
MX2020006365A (es) Quinazolinonas como inhibidores de poli(adenosin difosfato-ribosa)polimerasa 14 (parp14).
SG10201804000TA (en) Compositions for the treatment of rheumatoid arthritis and methods of using same
PH12018501894A1 (en) Compositions and methods for treating rheumatoid arthritis
PH12019502036A1 (en) Peptides and methods for the treatment of diabetes
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
EP4223786A3 (en) Novel anti-pad4 antibodies
MX2022009367A (es) Compuestos y usos de estos.
MX2022009366A (es) Compuestos y usos de estos.
MX2023005436A (es) Compuestos y usos de estos.
MX2022011897A (es) Composicion intraarticular para el tratamiento del cartilago y la artritis.
MX2022010925A (es) Compuestos para su uso en afecciones autoinmunitarias.
PH12020551331A1 (en) Treatment and prevention of pre-eclampsia
MX2020002147A (es) Composiciones útiles para la mejora del dolor.
EA201892183A1 (ru) Полиакриламидный гидрогель для применения в предупреждении и/или лечении синовита у млекопитающего
CR20200183A (es) Compuestos inhibidores de tirosina cinasa de bruton (btk)
MX2021014892A (es) Composiciones y metodos para el tratamiento del dolor en sujetos con artritis reumatoide.
MX2020010159A (es) Composiciones de creatina y/o creatinina y metodos relacionados.